DaVita HealthCare Partners Inc
$ 144.27
3.58%
11 Feb - close price
- Market Cap 9,310,728,000 USD
- Current Price $ 144.27
- High / Low $ 145.20 / 139.21
- Stock P/E 14.65
- Book Value -9.50
- EPS 9.51
- Next Earning Report 2026-02-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.65 %
- 52 Week High 178.38
- 52 Week Low 101.00
About
DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.
Analyst Target Price
$151.71
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-28 | 2025-08-05 | 2025-05-12 | 2025-02-13 | 2024-10-29 | 2024-08-06 | 2024-05-02 | 2024-02-13 | 2023-11-07 | 2023-08-03 | 2023-05-08 | 2023-02-22 |
| Reported EPS | 2.51 | 2.95 | 2 | 2.24 | 2.59 | 2.5 | 2.26 | 1.62 | 2.62 | 1.91 | 1.25 | 0.59 |
| Estimated EPS | 3.18 | 2.75 | 2.02 | 2.13 | 2.72 | 2.54 | 1.95 | 1.59 | 2.02 | 1.69 | 1.15 | 0.91 |
| Surprise | -0.67 | 0.2 | -0.02 | 0.11 | -0.13 | -0.04 | 0.31 | 0.03 | 0.6 | 0.22 | 0.1 | -0.32 |
| Surprise Percentage | -21.0692% | 7.2727% | -0.9901% | 5.1643% | -4.7794% | -1.5748% | 15.8974% | 1.8868% | 29.703% | 13.0178% | 8.6957% | -35.1648% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-18 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 3.1 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DVA
2026-02-11 10:35:00
DaVita Inc. (DVA) has experienced a significant resurgence in early 2026, overcoming previous skepticism related to GLP-1 drugs that were thought to threaten chronic kidney disease management. The company has transformed from a volume-based dialysis operator into a value-based manager of integrated kidney care, with its Integrated Kidney Care segment achieving profitability. Aggressive share buybacks, a clarified regulatory environment, and strong financial performance have driven its stock to new all-time highs.
2026-02-10 17:27:10
Ecolab Inc. (ECL) reported better-than-expected fourth-quarter and full-year 2025 financial results, with adjusted EPS and revenues surpassing Zacks Consensus Estimates. Despite the strong performance and expanded margins, the company's stock experienced a slight pre-market dip. Ecolab also provided an optimistic outlook for Q1 and full-year 2026, driven by accelerating organic sales growth, productivity initiatives, and strategic acquisitions like Ovivo Electronics.
2026-02-09 13:58:49
Shares of retail REIT Simon Property Group (SPG) rose 4% last week, fueled by strong Q4 earnings and a new $2 billion share buyback program. The company reported record Real Estate FFO and strong 2026 guidance, leading analysts to project a 13% upside to a $226 target price based on their valuation model. This positive outlook is supported by robust business execution, including increased occupancy rates, leasing activity, and strategic redevelopments.
/DaVita%20Inc%20sign%20on%20building-by%20photo-denver%20via%20Shutterstock.jpg)
2026-02-09 13:53:25
DaVita Inc. (DVA), a leading kidney care provider, has seen its stock decline by 18.2% over the past year due to rising costs and a ransomware attack. However, the stock is up 24% year-to-date after reporting stronger-than-expected Q4 2025 results. Wall Street analysts currently have a consensus "Hold" rating on DVA, with UBS maintaining a "Buy" rating and a $190 price target, suggesting a potential upside of 34.9%.
2026-02-09 05:58:37
DaVita (DVA) surpassed Q4 analyst expectations for revenue and non-GAAP profit, driven by revenue per treatment growth and strong performance in its Integrated Kidney Care (IKC) segment. Despite a decline in operating margin, CEO Javier Rodriguez highlighted progress in patient outcomes. This article details the key financial performance and five interesting analyst questions from the earnings call, covering topics like treatment volume growth, missed treatments, regulatory offsets, IKC profit improvement, and vaccination rates.
2026-02-08 22:04:00
Quest Diagnostics (DGX) is set to announce its Q4 earnings on Tuesday morning, with analysts expecting a 5.1% year-on-year revenue growth to $2.75 billion and adjusted earnings of $2.36 per share. The company has a history of exceeding Wall Street's revenue expectations. Despite debates over economic stability and a general underperformance in the healthcare providers & services segment, Quest has seen a 9.1% increase in share price over the last month.
